ETView Medical, Ltd., and MEDITRADE al. s ro, (MEDITRADE) Execute Distribution Agreement
Agreement allows Meditrade to exclusively market ETView's VivaSight™ products in Slovakia, Czech Republic and Poland
July 22, 2013 08:11 AM Eastern Daylight Time
TEL AVIV, Israel--(BUSINESS WIRE)--ETView Medical Ltd. (TASE: ETVW), announced today that it has entered into an exclusive distribution agreement with MEDITRADE al. s ro, (MEDITRADE). The agreement allows Meditrade to market ETView's VivaSight™ products which combine airway ventilation tubes with integrated continuous high resolution airway imaging for patient airway management and lung isolation capability in Slovakia, Czech Republic and Poland for a period of two years; other terms were not disclosed.
|William Edelman, CEO of ETView Medical commented, “We are excited to add MEDITRADE to our expanding distributor network.” Mr. Edelman continued, “VivaSight™ products are distributed in Europe, Asia, and the United States. VivaSight™ provides best-in-class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation.”||“We are excited to add MEDITRADE to our expanding distributor network."|
On June 10, 2013, ETView Medical, Ltd., announced an exclusive distribution agreement with Clinical Technologies, Inc., to market ETView's VivaSight™ products in the US states of North Dakota, South Dakota, Nebraska, Kansas, Missouri, Iowa, Minnesota, Wisconsin, Illinois, Kentucky, Indiana, Ohio, Michigan, and West Virginia.
On May 6, 2013, ETView Medical, Ltd., announced an exclusive distribution agreement with Mercury Medical, Inc., to market ETView's VivaSight™ products in Florida, Georgia, South Carolina, North Carolina, Virginia, Maryland, District of Columbia, Tennessee, Arkansas, Alabama, Mississippi, Louisiana, Texas, and Oklahoma.
On March 30, 2013, ETView Medical, Ltd., announced US FDA Clearance of a 510(k) Pre-marketing Notification Application expanding the VivaSight™-DL line of innovative airway devices.
On March 18, 2013, ETView Medical, Ltd. announced State Food and Drug Administration (SFDA, China) Clearance of a Pre-marketing Notification Application for the VivaSight™-SL line of innovative airway devices.
About MEDITRADE al. s ro
According to information provided to the company, MEDITRADE al. s ro, (MEDITRADE), based in Bratislava, Slovak Republic, is a leading specialty distributor of medical devices for cardiology and cardiovascular surgery. MEDITRADE represents ETView Medical, Boston Scientific, Johnson and Johnson and Abbot Laboratories.
About ETView Medical, Ltd.
ETView Medical Ltd. has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView's patented VivaSight™1 airway management portfolio consists of single-use disposable single and double lumen ventilation tubes with an integrated continuous high resolution airway imaging system. VivaSight™-SL and VivaSight™-DL are currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries. Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries.2
Typically, during lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Such intra-operative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.3 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4 accounting for over $250 million in single-use medical disposables.5 ETView has developed the VivaSight™ platform, combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway management and lung isolation capability, eliminating the need for fiberoptic bronchoscope6 imaging for intubation and airway monitoring in lung isolation procedures.
The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward-looking statements, as such term is defined under the Israeli Securities Law (5728-1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.
1 Patents issued and pending
2 Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 2011
3 Anesthesia & Analgesia. 2009;108:1097–101
4 National Health Statistics Reports Number 29, October 26, 2010
5 Company estimates on file
6 Minerva Anestesiol. 2009;75 (Suppl 1):1-4.